Abraxis Pharmaceutical Products (ABBI) Receives Two FDA Approvals
More News related to ABBI
- Abraxis Pharmaceutical Products (ABBI) Receives Two FDA Approvals
- Abraxis BioScience (ABBI) Receives Tentative FDA Approval for Generic Camptosar Injection
- Abraxis BioScience (ABBI) Receives Tentative FDA Approval for Granisetron
- Abraxis BioScience (ABBI) Tops Q2 EPS by 5c, Revs Light
- Abraxis BioScience (ABBI) Acquires Intellectual Property Rights for Technologies Designed to Discover New Drug Candidates from Buck Institute
More News related to FDA
- Highlights From DIVX's Q3 Conference Call; Licensing Business Transitioning to New Growth Categories; Guides Above for Q4 EPS
- Toll Brothers (TOL) Changes Q4 Financials Release Date to November 10,
- Highlights From ERTS's Q2 Conference Call: Largest Quarter for Digital Direct Revenues in EA's History; Guides In-line
- Highlights From PCLN's Q3 Conference Call: Bookings Up 33% Year-Over-Year, Guides Above for Q4
- CPI Aerostructures (CVU) Posts Q3 EPS of $0.15, Misses Estimates; Revs Light
Abraxis Pharmaceutical Products (Nasdaq: ABBI) today announced it has received approval from the Food and Drug Administration for two products, a lyophilized version and a liquid version of Fludarabine phosphate. Fludarabine is used for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen.
Abraxis Pharmaceutical manufactures and markets one of the most comprehensive injectable portfolios of products to the U.S. hospital-based market. The current injectable portfolio is comprised of anti-infectives, critical care, oncology and anesthetic/analgesic products totaling over 400 dosage forms
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
